Outlook Therapeutics Reports Q2 Fiscal 2026 Revenue Growth to $127,439 Amid Ongoing Losses

Outlook Therapeutics, Inc. reported its financial results for the second quarter of fiscal 2026, revealing a net revenue of $127,439, a significant increase from zero in the same period last year. However, the company continues to face substantial losses, with a net loss of $4.5 million for the quarter, compared to a loss of $46.4 million in the prior year. For the six months ending March 31, 2026, the company recorded a net loss of $27.5 million, a slight improvement from a loss of $29 million during the same period in 2025. The increase in revenue is attributed to the commercial launch of LYTENAVA (bevacizumab gamma) in Germany and the UK, which began in June 2025.

In terms of operational metrics, Outlook Therapeutics has seen a notable shift in its financial structure. The company’s total assets increased to $21.9 million as of March 31, 2026, up from $18.6 million at the end of the previous fiscal year. This growth is primarily due to an increase in accounts receivable and prepaid expenses. The company’s liabilities, however, remain high, totaling $50.9 million, with a significant portion attributed to convertible promissory notes. The current portion of these notes decreased from $29.9 million to $9.8 million, reflecting recent conversions into common stock.

Strategically, Outlook Therapeutics has made significant progress in its product development and regulatory efforts. The company is actively working with the FDA to address the requirements for its Biologics License Application (BLA) for ONS-5010/LYTENAVA. Following a series of Complete Response Letters (CRLs) from the FDA, the company has engaged in discussions to clarify the regulatory pathway and has submitted a formal dispute resolution request. The company is also exploring additional financing options to support its operations, including potential licensing agreements and equity offerings.

The company’s operational focus remains on expanding its market presence in Europe and preparing for potential launches in the U.S. if regulatory approval is granted. Outlook Therapeutics has indicated that it may need to secure additional funding to continue its operations, as current cash reserves are insufficient to cover expenses for the next year. The company is evaluating various strategies, including partnerships and equity sales, to bolster its financial position. As of March 31, 2026, Outlook Therapeutics had a working capital deficit and an accumulated deficit of $633.2 million, raising concerns about its ability to continue as a going concern without further financing.